MX2012006420A - Metodos para mejorar terapia con anticuerpos antitumor. - Google Patents

Metodos para mejorar terapia con anticuerpos antitumor.

Info

Publication number
MX2012006420A
MX2012006420A MX2012006420A MX2012006420A MX2012006420A MX 2012006420 A MX2012006420 A MX 2012006420A MX 2012006420 A MX2012006420 A MX 2012006420A MX 2012006420 A MX2012006420 A MX 2012006420A MX 2012006420 A MX2012006420 A MX 2012006420A
Authority
MX
Mexico
Prior art keywords
methods
antibody therapy
tumor antibody
enhancing anti
antibody
Prior art date
Application number
MX2012006420A
Other languages
English (en)
Other versions
MX346912B (es
Inventor
Holbrook Kohrt
Roch Houot
Ronald Levy
Matthew J Goldstein
James Torchia
Arash Ash Alizadeh
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of MX2012006420A publication Critical patent/MX2012006420A/es
Publication of MX346912B publication Critical patent/MX346912B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención tiene por objeto métodos para aumentar la eficacia de la citotoxicidad celular dirigida por un anticuerpo (ADCC) para terapia dirigida a la destrucción de células tumorales. Los antígenos de la superficie celular específicos de un cáncer se unen por anticuerpos monoclonales, estimulando así una respuesta de células T citotóxicas caracterizada por una sobrerregulación de la expresión por la superficie celular de moléculas coestimuladoras en la célula T. La respuesta de ADCC aumenta por la administración subsiguiente de un segundo anticuerpo que es un agonista de la molécula coestimuladora.
MX2012006420A 2009-12-07 2010-12-07 Metodos para mejorar terapia con anticuerpos antitumor. MX346912B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26733709P 2009-12-07 2009-12-07
US28706709P 2009-12-16 2009-12-16
US35830310P 2010-06-24 2010-06-24
PCT/US2010/059221 WO2011071871A1 (en) 2009-12-07 2010-12-07 Methods for enhancing anti-tumor antibody therapy

Publications (2)

Publication Number Publication Date
MX2012006420A true MX2012006420A (es) 2012-12-05
MX346912B MX346912B (es) 2017-04-05

Family

ID=44145876

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012006420A MX346912B (es) 2009-12-07 2010-12-07 Metodos para mejorar terapia con anticuerpos antitumor.

Country Status (11)

Country Link
US (3) US9005619B2 (es)
EP (1) EP2509627B1 (es)
JP (1) JP5950824B2 (es)
KR (1) KR101853702B1 (es)
CN (1) CN102753195A (es)
AU (3) AU2010328347B2 (es)
BR (1) BR112012013736A2 (es)
CA (1) CA2781311C (es)
MX (1) MX346912B (es)
SG (2) SG10201501784YA (es)
WO (1) WO2011071871A1 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102574924A (zh) 2009-09-03 2012-07-11 先灵公司 抗-gitr抗体
KR101853702B1 (ko) * 2009-12-07 2018-05-03 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 항-종양 항체 치료를 향상시키는 방법
DK2609118T3 (en) 2010-08-23 2017-04-03 Univ Texas Anti-OX40 antibodies and methods for their use
PE20131465A1 (es) 2010-09-09 2014-01-04 Pfizer Moleculas de union a 4-1 bb
CA2830972C (en) * 2011-04-19 2018-11-20 Pfizer Inc. Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
JP2016534090A (ja) * 2013-07-15 2016-11-04 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Ｃｄ３８アゴニストの医学的使用
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
KR20160146747A (ko) 2014-03-31 2016-12-21 제넨테크, 인크. 항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법
CN115925946A (zh) 2014-05-28 2023-04-07 阿吉纳斯公司 抗gitr抗体和其使用方法
WO2015188047A1 (en) * 2014-06-06 2015-12-10 University Of Maryland, Baltimore ANTI-CD-137 MONOCLONAL ANTIBODIES WITH DISTINCT FcγR BINDING ABILITIES FOR TREATMENT OF CANCER OR AUTOIMMUNITY
US10463732B2 (en) * 2014-10-03 2019-11-05 Dana-Farber Cancer Institute, Inc. Glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies and methods of use thereof
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
MA41414A (fr) * 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
PT3273992T (pt) 2015-03-23 2020-08-21 Jounce Therapeutics Inc Anticorpos para icos
WO2016167809A1 (en) * 2015-04-17 2016-10-20 The Board Of Trustees Of The Leland Stanford Junior University Improved t-dm1 therapy
EP3091031A1 (en) * 2015-05-04 2016-11-09 Affimed GmbH Combination of a bispecific antibody with an immune modulating molecule for the treatment of a tumor
EP3292152A1 (en) 2015-05-07 2018-03-14 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
RS63897B1 (sr) 2015-05-29 2023-02-28 Bristol Myers Squibb Co Antitela protiv ox40 i njihova primena
WO2017005845A1 (en) * 2015-07-07 2017-01-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for enhancing nk cell killing activities
CA2992298A1 (en) 2015-07-23 2017-01-26 Inhibrx Lp Multivalent and multispecific gitr-binding fusion proteins
WO2017040374A1 (en) 2015-08-31 2017-03-09 The Trustees Of The University Of Pennsylvania Compositions and methods of enhancing anti-tumor response using hybrid neutrophils
CA2992863A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific antibodies specific for a costimulatory tnf receptor
EP3365372A1 (en) 2015-10-22 2018-08-29 Jounce Therapeutics, Inc. Gene signatures for determining icos expression
MA44312A (fr) 2015-12-02 2018-10-10 Agenus Inc Anticorps et leurs méthodes d'utilisation
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018005950A1 (en) 2016-07-01 2018-01-04 Five Prime Therapeutics, Inc. Combined anti tumor therapy with a gitr agonist and cpg
GB201613167D0 (en) * 2016-07-29 2016-09-14 Univ Southampton Cancer and b-cell related disease therapy
JP2019530434A (ja) 2016-08-05 2019-10-24 ジェネンテック， インコーポレイテッド アゴニスト活性を有する多価及び多重エピトープ抗体ならびに使用方法
JP7198752B2 (ja) 2016-08-09 2023-01-04 カイマブ・リミテッド 抗ｉｃｏｓ抗体
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
WO2018089628A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
BR112019017628A2 (pt) 2017-02-24 2020-07-07 Macrogenics, Inc. molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
CN110546166B (zh) 2017-04-13 2024-03-29 艾吉纳斯公司 抗cd137抗体和其使用方法
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
JP7402521B2 (ja) 2017-07-11 2023-12-21 コンパス セラピューティクス リミテッド ライアビリティ カンパニー ヒトｃｄ１３７に結合するアゴニスト性抗体およびその使用
EP3682237A1 (en) 2017-09-15 2020-07-22 Beckman Coulter, Inc. Flow based assays for therapeutics
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
EP3713961A2 (en) 2017-11-20 2020-09-30 Compass Therapeutics LLC Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
EP3728314A1 (en) 2017-12-19 2020-10-28 Kymab Limited Bispecific antibody for icos and pd-l1
TWI841551B (zh) * 2018-03-13 2024-05-11 瑞士商赫孚孟拉羅股份公司 使用靶向4-1bb (cd137)之促效劑的組合療法
KR20210035805A (ko) 2018-06-15 2021-04-01 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
US20200046737A1 (en) * 2018-08-09 2020-02-13 Notable Labs, Inc. Methods for treating cancer, and compositions therefor
KR20200030337A (ko) * 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
CA3127072A1 (en) * 2019-01-16 2020-07-23 Compass Therapeutics Llc Formulations of antibodies that bind human cd137 and uses thereof
US20230135930A1 (en) 2019-04-24 2023-05-04 Heidelberg Pharma Research Gmbh Amatoxin antibody-drug conjugates and uses thereof
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
KR20220092529A (ko) * 2019-10-18 2022-07-01 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 Nk 세포 수용체 결합을 위한 다중 리간드와 접합된 나노입자를 사용하는 암 치료 방법 및 조성물
WO2021127217A1 (en) 2019-12-17 2021-06-24 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
WO2021202917A1 (en) * 2020-04-01 2021-10-07 The Board Of Trustees Of The Leland Stanford Junior University A noninvasive multiparameter approach for early identification of therapeutic benefit from immune checkpoint inhibition for lung cancer
CN113491768A (zh) * 2020-04-01 2021-10-12 深圳市罗湖区人民医院 Cd137抗体在制备促进nk细胞表达cd16分子的药物中的应用
CA3184366A1 (en) 2020-06-29 2022-01-06 Darby Rye Schmidt Viruses engineered to promote thanotransmission and their use in treating cancer
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
CA3202218A1 (en) 2020-12-18 2022-06-23 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
KR20230165276A (ko) 2021-03-31 2023-12-05 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션 폴리펩티드 및 암의 치료에서의 이의 용도
JP2024525475A (ja) 2021-06-29 2024-07-12 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド タノトランスミッションを促進するように操作された免疫細胞及びその使用
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030035790A1 (en) * 1999-01-15 2003-02-20 Shu-Hsia Chen Combination therapy for the prevention or treatment of cancer, inflammatory disorders or infectious diseases in a subject
US20040018194A1 (en) * 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
TW200303759A (en) 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
FR2844513B1 (fr) 2002-09-13 2007-08-03 Lab Francais Du Fractionnement Anticorps pour adcc et induisant la production de cytokines.
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
EP1802660A2 (en) 2004-09-08 2007-07-04 Genentech, Inc. Methods of using death receptor ligands and cd20 antibodies
WO2006116246A2 (en) * 2005-04-25 2006-11-02 Medarex, Inc. Method of treating cd30 positive lymphomas
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007024715A2 (en) * 2005-08-19 2007-03-01 Abbott Laboratories Dual variable domain immunoglobin and uses thereof
US20080003225A1 (en) 2006-06-29 2008-01-03 Henri Vie Method for enhancing the antibody-dependent cellular cytotoxicity (ADCC) and uses of T cells expressing CD16 receptors
WO2010042433A1 (en) 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
KR101853702B1 (ko) * 2009-12-07 2018-05-03 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 항-종양 항체 치료를 향상시키는 방법
EP2571577A1 (en) 2010-05-17 2013-03-27 Bristol-Myers Squibb Company Improved immunotherapeutic dosing regimens and combinations thereof
WO2012027536A1 (en) 2010-08-26 2012-03-01 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with braf inhibitors for the synergistic treatment of proliferative diseases
CN103476407A (zh) 2010-12-09 2013-12-25 霍夫曼-拉罗奇有限公司 用帕利他赛和曲妥珠单抗-mcc-dm1治疗her2阳性癌症
CN103566377A (zh) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
MX367042B (es) 2012-10-02 2019-08-02 Bristol Myers Squibb Co Combinacion de anticuerpos anti-kir y anticuerpos anti-dp-1 para tratar cancer.
EP2912063A1 (en) 2012-10-23 2015-09-02 Bristol-Myers Squibb Company Combination of anti-kir and anti-ctla-4 antibodies to treat cancer

Also Published As

Publication number Publication date
US9758589B2 (en) 2017-09-12
CA2781311C (en) 2019-03-12
AU2017268492A1 (en) 2017-12-14
AU2010328347A1 (en) 2012-06-21
EP2509627A1 (en) 2012-10-17
AU2016201190A1 (en) 2016-03-17
US9005619B2 (en) 2015-04-14
AU2010328347B2 (en) 2015-12-17
MX346912B (es) 2017-04-05
KR101853702B1 (ko) 2018-05-03
CN102753195A (zh) 2012-10-24
US20120321646A1 (en) 2012-12-20
BR112012013736A2 (pt) 2018-08-14
US10633450B2 (en) 2020-04-28
WO2011071871A1 (en) 2011-06-16
JP2013512958A (ja) 2013-04-18
US20180208670A1 (en) 2018-07-26
SG10201501784YA (en) 2015-05-28
EP2509627A4 (en) 2013-12-25
JP5950824B2 (ja) 2016-07-13
US20160083474A1 (en) 2016-03-24
KR20120102714A (ko) 2012-09-18
EP2509627B1 (en) 2017-01-25
SG181533A1 (en) 2012-07-30
CA2781311A1 (en) 2011-06-16

Similar Documents

Publication Publication Date Title
MX2012006420A (es) Metodos para mejorar terapia con anticuerpos antitumor.
MY164661A (en) Novel immunoconjugates
WO2008070042A3 (en) High potency recombinant antibodies, methods for producing them and use in cancer therapy
WO2012135854A3 (en) T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2
MX2021010441A (es) Receptores antigenicos quimericos y agentes de union dirigidos a dll3.
EP3539988A3 (en) Monoclonal antibodies against her2
PH12016500349B1 (en) Anti-prlr antibodies and uses thereof
MY192474A (en) Chimeric antigen receptors targeting epidermal growth factor receptor variant iii
MX2010005830A (es) Conjugado de anticuerpo monoclonal anti-b7h4 - farmaco y metodos de uso del mismo.
NZ731633A (en) Antibodies against cd73 and uses thereof
MX2013011706A (es) Proteinas novedosas de enlace a antigeno.
UA114879C2 (uk) Антитіло до cd38 для лікування раку
WO2015012904A3 (en) Antibody-sn-38 immunoconjugates with a cl2a linker
WO2009014708A3 (en) Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
MX341076B (es) Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
CA3019531A1 (en) Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
WO2006089231A3 (en) Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
EP2348052A3 (en) Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
MX346973B (es) Anticuerpos especificos de tumores y usos para los mismos.
SI2125897T1 (en) MONOCOLONIAL PROTITELES AGAINST GT 468 FOR CARRYING CANCER
CR20120429A (es) Métodos para el tratamiento contra carcinoma escamocelular de cabeza y cuello
ZA202008095B (en) Humanized antibodies against psma
WO2011133819A3 (en) Methods of enhancing antibody-dependent cellular cytotoxicity
MX2021011750A (es) Anticuerpos anti-egfrviii y fragmentos de union a antigenos de los mismos.
EA200970884A1 (ru) Способы лечения рака путем введения комбинаций человеческого интерлейкина ил-18

Legal Events

Date Code Title Description
FG Grant or registration